<DOC>
	<DOCNO>NCT02117258</DOCNO>
	<brief_summary>The primary objective study compare efficacy GEM plus Z-360 versus GEM plus placebo overall survival ( OS ) subject metastatic Pancreatic Adenocarcinoma .</brief_summary>
	<brief_title>Z-360 Plus GEM Subjects With Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Subjects histological cytological evidence metastatic Pancreatic Adenocarcinoma , Measurable disease nonmeasurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) version criterion 2 . Subjects life expectancy least 12 week , 3 . Subjects Eastern cooperative oncology group performance status ( ECOG PS ) 0 , 1 2 , 4 . Subjects follow adequate organ function : White blood cell count ≥3,000/μL ( absolute neutrophil count ≥1,500/μL ) ≤ 12,000/μL , Platelet count ≥100.0 × 10^9/L , Hemoglobin ≥9.0 g/dL , Serum creatinine ≤1.5 × upper limit normal ( ULN ) , Total bilirubin ≤2.0 × ULN , Serum aspartate transaminase level ≤3.0 × ULN ( ≤5.0 × ULN presence liver metastasis ) , Serum alanine aminotransferase level ≤3.0 × ULN ( ≤5.0 × ULN presence liver metastasis ) . Subjects receive follow previous therapy Pancreatic Adenocarcinoma : Surgery within 4 week prior randomization , Radiation chemoradiation within 12 week prior randomization , Radiation pain relief within 4 week prior randomization , Gemcitabine use neoadjuvant adjuvant surgery within 24 week prior randomization , Chemotherapy except GEM use adjuvant surgery within 4 week prior randomization , Gemcitabine ≥600 mg/m^2 sensitizer chemoradiation , Gemcitabine &lt; 600 mg/m^2 sensitizer chemoradiation within 12 week prior randomization , Gemcitabine use systemic chemotherapy , Systemic chemotherapies except GEM within 4 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Z-360 , Pancreatic cancer , Pancreatic Adenocarcinoma</keyword>
</DOC>